BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Agile Therapeutics, Inc. to Present at Elsevier Business Intelligence's Therapeutic Area Partnerships


11/29/2012 9:08:22 AM

PRINCETON, NJ--(Marketwire - November 29, 2012) -

Agile Therapeutics announced today that Al Altomari, President and CEO of Agile Therapeutics, will be presenting at Elsevier Business Intelligence's Therapeutic Area Partnerships, taking place November 28-30 in Boston. Agile has been named as a "Top 10 Hot Space Projects to Watch" by Elsevier and will be giving a company presentation on November 29 at 3:40 pm Eastern time.

Mr. Altomari's presentation will provide an overview of the Company's recent milestones, its pipeline of products, and its growth strategy. Agile's lead investigational product is AG200-15, which is designed to be a once-weekly, low-dose contraceptive patch. The Company recently filed the NDA for AG200-15, and anticipates a response in 2013.

Elsevier considered various criteria when selecting the Top 10 Hot Space Projects to Watch, including the strength of the science behind the company's product(s), the market size for the company's product(s), and the unmet need for the company's product(s).

"It is an honor to be selected as a top project to watch by Elsevier," said Mr. Altomari. "We are proud of the work we have done in developing AG200-15, and we look forward to discussing this progress, as well as our pipeline of products and future plans, at Therapeutic Area Partnerships."

About AG200-15
AG200-15 is an investigational combination hormonal contraceptive patch, designed to deliver a low dose of ethinyl estradiol comparable to low-dose combination oral contraceptives. The phase III trials for AG200-15 enrolled nearly 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012.

The AG200-15 patch is intended to be applied once weekly for three weeks, followed by a fourth, patch-free week. The patch is designed using a soft, flexible cloth, with a silky feel, and is intended to provide excellent adhesion, comfort, and appearance.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and potentially more convenient methods of hormonal contraception. The Company's lead investigational product, AG200-15, is designed to be a once-weekly contraceptive patch that has recently been submitted to the FDA as a New Drug Application (NDA) for review. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that has been designed to allow stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.


Contact
Chantal Beaudry/Karen Famighetti for Agile Therapeutics
212-867-1762
cbeaudry@lazarpartners.com
kfamighetti@lazarpartners.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES